Rapidly commercialising advanced therapies: Creating the first-ever scaled-out bioprocess system
TTP used our extensive experience of commercialising advanced therapies to help Amgen rapidly bring Erythropoietin (EPO) to market. We created a highly scaled-out bioprocessing system containing 40,000 roller bottles.
Client
Amgen
Industries
Bioprocesses, Cell and Gene Therapy, Life Science
Context
Challenges with scaling-up and manufacturing cell and gene therapies are incredibly common and cause significant delays in patient access to living medicines.
Solution
TTP created the first highly scaled-out, rather than scaled-up, bioprocessing system. We designed and built a factory that contained 40,000 roller bottles conducting parallel manufacturing.
Result
Amgen were able to quickly commercialise EPO and avoided major delays associated with redeveloping and revalidating their manufacturing process for a different format.
Scaling-out rather than scaling-up: Enabling Amgen to overcome barriers with advanced therapy commercialisation
Cell and gene therapies offer potential cures for some of the most devastating and challenging conditions of our time. However, patients face delays in accessing the latest innovations, which are often caused by manufacturing or scaling barriers. Amgen approached TTP to help them overcome this challenge when trying to commercialise EPO.
In partnership with Amgen, TTP was the first company to scale out rather than scale-up bioprocessing manufacturing. Using our experience and expertise in cell and gene therapies, we supported Amgen in moving from a small volume of roller bottles to many roller bottles, rather than scaling up to large-volume bioreactors.
Together, we designed and built a factory that contained 40,000 roller bottles conducting parallel manufacturing that directly replicated the biology of the small-scale process. TTP combined inventive thinking and experience to solve the challenges of having thousands of individual parts operating as a single system to provide a reliable and robust cell therapy manufacturing solution. Amgen avoided the time-consuming process of redevelopment, and critical revalidation, of the manufacturing process on a new format.
TTP’s heritage in cell and gene therapies equips us to anticipate and solve potential gaps and challenges across the entire development process. Throughout our thirty years of experience, we have helped over 20 cell therapy companies to use disruptive technologies and automation to solve the most demanding commercialisation and scaling challenges.
